Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Ge-gen-tang (GGT), known as Kakkonto in Japanese Kampo medicine, is a traditional herbal formula composed of seven medicinal plants: Puerariae Lobatae Radix, Ephedrae Herba, Zingiberis Rhizoma, Paeoniae Radix, Cinnamomi Ramulus, Glycyrrhizae Radix, and Jujubae Fructus. It is traditionally indicated for the early stages of exogenous febrile diseases, such as the common cold and influenza, characterized by fever, chills, and neck stiffness. In the context of COVID-19, GGT has been investigated for its potential to modulate the immune response and inhibit the cytokine storm by reducing levels of pro-inflammatory cytokines like IL-6 and TNF-α. Its mechanism of action involves anti-inflammatory, antipyretic, and antiviral properties, potentially interfering with viral attachment and replication while alleviating respiratory symptoms through the regulation of prostaglandin production and immune cell activity.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on ge-gen-tang.